The ICG manages the global stockpile of Ebola vaccine which was created as an additional tool to help control Ebola virus disease (EVD) outbreaks. As EVD outbreaks are relatively rare and unpredictable in nature, and due to limited vaccine availability, the current Ervebo vaccine is reserved for outbreak response to protect people at the highest risk of contracting EVD – including health care and frontline workers in an outbreak – under a ring vaccination strategy.

Following SAGE recommendations, a global stockpile of 500,000 doses of Ebola vaccine has been constitute and will be available at all times for outbreak response. The ICG works with partners and stakeholders to use Ervebo vaccine in the context of an integrated EVD outbreak response strategy based on early detection, contact tracing, case management, infection prevention and control measures, safe and dignified burials, and raising awareness among the affected communities.

To request access to ICG Ebola vaccine stocks, the country should submit the Ebola ICG request form, annexes and other required documents, as per the checklist in the request form, to the This email address is being protected from spambots. You need JavaScript enabled to view it. (WHO Geneva).  Any ICG member agency (IRFC, MSF, UNICEF, WHO) present in the country can also submit the application on behalf of the Ministry of Health. It is highly recommended that the country submits the request to the ICG secretariat within 7 days after confirmation of the outbreak. The ICG secretariat at WHO then circulates the request to the members (IFRC, MSF, UNICEF, and WHO) for review and assessment within 1 day after receiving the request. Additional information can be requested to the country, if needed.

Requests are evaluated taking into account the epidemiological situation, vaccination strategy, pre-existing stocks in the country and operational aspects of the epidemic response.